Literature DB >> 23319164

Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.

Maria-Giulia Perrelli1, Francesca Tullio, Carmelina Angotti, Maria Carmela Cerra, Tommaso Angelone, Bruno Tota, Giuseppe Alloatti, Claudia Penna, Pasquale Pagliaro.   

Abstract

Catestatin (CST) limits myocardial ischaemia/reperfusion (I/R) injury with unknown mechanisms. Clearly phosphoinositide-3-kinase (PI3K), protein kinase C (PKC) isoforms, including intra-mitochondrial PKCε, mitochondrial KATP (mitoKATP) channels and subsequent reactive oxygen species (ROS)-signalling play important roles in postconditioning cardioprotection, preventing mitochondrial permeability transition pore (mPTP) opening. Therefore, we studied the role of these extra- and intra-mitochondrial factors in CST-induced protection. Isolated rat hearts and H9c2 cells underwent I/R and oxidative stress, respectively. In isolated hearts CST (75nM, CST-Post) given in early-reperfusion significantly reduced infarct size, limited post-ischaemic contracture, and improved recovery of developed left ventricular pressure. PI3K inhibitor, LY-294002 (LY), large spectrum PKC inhibitor, Chelerythrine (CHE), specific PKCε inhibitor (εV1-2), mitoKATP channel blocker, 5-Hydroxydecanoate (5HD) or ROS scavenger, 2-mercaptopropionylglycine (MPG) abolished the infarct-sparing effect of CST. Notably the CST-induced contracture limitation was maintained during co-infusion of 5HD, MPG or εV1-2, but it was lost during co-infusion of LY or CHE. In H9c2 cells challenged with H2O2, mitochondrial depolarization (an index of mPTP opening studied with JC1-probe) was drastically limited by CST (75nM). Our results suggest that the protective signalling pathway activated by CST includes mitoKATP channels, ROS signalling and prevention of mPTP opening, with a central role for upstream PI3K/Akt and PKCs. In fact, all inhibitors completely abolished CST-infarct-sparing effect. Since CST-anti-contracture effect cannot be explained by intra-mitochondrial mechanisms (PKCε activation and mitoKATP channel opening) or ROS signalling, it is proposed that these downstream signals are part of a reverberant loop which re-activates upstream PKCs, which therefore play a pivotal role in CST-induced protection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319164     DOI: 10.1007/s00424-013-1217-0

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  56 in total

Review 1.  The multidimensional physiological responses to postconditioning.

Authors:  Jakob Vinten-Johansen; Asger Granfeldt; James Mykytenko; Vishnu V Undyala; Yi Dong; Karin Przyklenk
Journal:  Antioxid Redox Signal       Date:  2010-11-02       Impact factor: 8.401

2.  Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade.

Authors:  Sebastian Philipp; Xi-Ming Yang; Lin Cui; Amanda M Davis; James M Downey; Michael V Cohen
Journal:  Cardiovasc Res       Date:  2006-02-23       Impact factor: 10.787

Review 3.  Mitochondria in postconditioning.

Authors:  Kerstin Boengler; Gerd Heusch; Rainer Schulz
Journal:  Antioxid Redox Signal       Date:  2010-09-29       Impact factor: 8.401

Review 4.  Postconditioning in acute myocardial infarction patients.

Authors:  Fabrice Ivanes; Gilles Rioufol; Christophe Piot; Michel Ovize
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

5.  Role of calreticulin in the sensitivity of myocardiac H9c2 cells to oxidative stress caused by hydrogen peroxide.

Authors:  Yoshito Ihara; Yoshishige Urata; Shinji Goto; Takahito Kondo
Journal:  Am J Physiol Cell Physiol       Date:  2005-08-31       Impact factor: 4.249

6.  Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling.

Authors:  Amanda J Zatta; Hajime Kin; George Lee; Ningping Wang; Rong Jiang; Robert Lust; James G Reeves; James Mykytenko; Robert A Guyton; Zhi-Qing Zhao; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2006-01-27       Impact factor: 10.787

7.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

Review 8.  Chromogranin-A: a multifaceted cardiovascular role in health and disease.

Authors:  T Angelone; R Mazza; M C Cerra
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

9.  ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes.

Authors:  Jiahao Liu; Weike Mao; Bo Ding; Chang-seng Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-05       Impact factor: 4.733

10.  Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.

Authors:  Sandra Cappello; Tommaso Angelone; Bruno Tota; Pasquale Pagliaro; Claudia Penna; Raffaella Rastaldo; Angelo Corti; Gianni Losano; Maria Carmela Cerra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-06       Impact factor: 4.733

View more
  24 in total

Review 1.  Autophagy, a process within reperfusion injury: an update.

Authors:  Bisharad Anil Thapalia; Zhen Zhou; Xianhe Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 2.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

3.  Remifentanil functions in the adaptive protection of cardiac function following ischemia.

Authors:  Jie Hou; Huishan Wang; Xinmin Li; Yan Zhu
Journal:  Exp Ther Med       Date:  2017-02-15       Impact factor: 2.447

4.  pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury.

Authors:  T Pasqua; B Tota; C Penna; A Corti; M C Cerra; P Loh Y; T Angelone
Journal:  J Endocrinol       Date:  2015-09-23       Impact factor: 4.286

Review 5.  Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Authors:  Anett H Ottesen; Geir Christensen; Torbjørn Omland; Helge Røsjø
Journal:  Curr Heart Fail Rep       Date:  2017-12

6.  Cardiac and hepatic role of r-AtHSP70: basal effects and protection against ischemic and sepsis conditions.

Authors:  Teresa Pasqua; Elisabetta Filice; Rosa Mazza; Anna Maria Quintieri; Maria Carmela Cerra; Rina Iannacone; Donato Melfi; Cesare Indiveri; Alfonsina Gattuso; Tommaso Angelone
Journal:  J Cell Mol Med       Date:  2015-04-23       Impact factor: 5.310

7.  Merit of anisodamine combined with opioid δ-receptor activation in the protection against myocardial injury during cardiopulmonary bypass.

Authors:  Xuan Hong; Huimin Fan; Rong Lu; Paul Chan; Zhongmin Liu
Journal:  Biomed Res Int       Date:  2013-12-10       Impact factor: 3.411

8.  Ginsenoside RK3 Prevents Hypoxia-Reoxygenation Induced Apoptosis in H9c2 Cardiomyocytes via AKT and MAPK Pathway.

Authors:  Jing Sun; Guibo Sun; Xiangbao Meng; Hongwei Wang; Min Wang; Meng Qin; Bo Ma; Yun Luo; Yingli Yu; Rongchang Chen; Qidi Ai; Xiaobo Sun
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-27       Impact factor: 2.629

9.  Catestatin attenuates endoplasmic reticulum induced cell apoptosis by activation type 2 muscarinic acetylcholine receptor in cardiac ischemia/reperfusion.

Authors:  Feng Liao; Yang Zheng; Junyan Cai; Jinghui Fan; Jing Wang; Jichun Yang; Qinghua Cui; Guoheng Xu; Chaoshu Tang; Bin Geng
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

10.  Catestatin increases the expression of anti-apoptotic and pro-angiogenetic factors in the post-ischemic hypertrophied heart of SHR.

Authors:  Claudia Penna; Teresa Pasqua; Daniela Amelio; Maria-Giulia Perrelli; Carmelina Angotti; Francesca Tullio; Sushil K Mahata; Bruno Tota; Pasquale Pagliaro; Maria C Cerra; Tommaso Angelone
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.